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Autosomal recessive cerebellar ataxias (ARCAs) form an ultrarare yet expanding
group of neurodegenerative multisystemic diseases affecting the cerebellum and other
neurological or non-neurological systems. With the advent of targeted therapies for
ARCAs, disease registries have become a precious source of real-world quantitative
and qualitative data complementing knowledge from preclinical studies and clinical
trials. Here, we review the ARCA Registry, a global collaborative multicenter platform
(>15 countries, >30 sites) with the overarching goal to advance trial readiness in
ARCAs. It presents a good clinical practice (GCP)- and general data protection regulation
(GDPR)-compliant professional-reported registry for multicenter web-based capture
of cross-center standardized longitudinal data. Modular electronic case report forms
(eCRFs) with core, extended, and optional datasets allow data capture tailored to
the participating site’s variable interests and resources. The eCRFs cover all key
data elements required by regulatory authorities [European Medicines Agency (EMA)]
and the European Rare Disease (ERD) platform. They capture genotype, phenotype,
and progression and include demographic data, biomarkers, comorbidity, medication,
magnetic resonance imaging (MRI), and longitudinal clinician- or patient-reported ratings
of ataxia severity, non-ataxia features, disease stage, activities of daily living, and (mental)
health status. Moreover, they are aligned to major autosomal-dominant spinocerebellar
ataxia (SCA) and sporadic ataxia (SPORTAX) registries in the field, thus allowing for joint
and comparative analyses not only across ARCAs but also with SCAs and sporadic
ataxias. The registry is at the core of a systematic multi-component ARCA database
cluster with a linked biobank and an evolving study database for digital outcome
measures. Currently, the registry contains more than 800 patients with almost 1,500
visits representing all ages and disease stages; 65% of patients with established genetic
diagnoses capture all the main ARCA genes, and 35% with unsolved diagnoses are
targets for advanced next-generation sequencing. The ARCA Registry serves as the
backbone of many major European and transatlantic consortia, such as PREPARE,
PROSPAX, and the Ataxia Global Initiative, with additional data input from SPORTAX.
It has thus become the largest global trial-readiness registry in the ARCA field.
Keywords: ataxia, registry, network, natural history, trial readiness
ARCA REGISTRY: THE OVERARCHING
GOAL
Autosomal recessive cerebellar ataxias (ARCAs) are
a heterogeneous group of ultrarare multisystemic
neurodegenerative diseases affecting the cerebellum and/or
its afferent tracts, often accompanied by damage to other
neurological (e.g., corticospinal tract, basal ganglia, vestibular
system, and peripheral nerves) or non-neurological systems (e.g.,
muscle, heart, and pancreas) (1, 2). The number of ARCA genes
is continuously expanding, extending far above >100 genes,
and the first ARCAs now come into reach of targeted treatment
options (2).
Disease registries have been important for identification,
characterization, and aggregation of rare neurological diseases.
However, the real-world quantitative and qualitative evidence
in registries and registry-based natural history and outcome
measure studies have now also become a precious source for
planning of treatment trials and modeling trial designs and
endpoints, thereby complementing the knowledge available from
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preclinical studies and clinical trials (3). The ARCA Registry
was launched in 2013 in order to apply this concept to the
field of ARCAs, and it remains the only multicenter registry
fully dedicated to ARCAs and early-onset ataxias (EOAs), which
are known to be enriched but not exclusive for ARCAs (1, 2).
The overarching goal of the ARCA Registry is to become a key
facilitator enabling trial readiness by
• providing an easily accessible, web-based, good clinical
practice (GCP)-conforming, and general data protection
regulation (GDPR)-compliant multicenter multi-trial registry
infrastructure platform as a backbone for global trial-readiness
efforts in ARCAs;
• building cohorts of sufficient size for trial-readiness studies
and upcoming treatment trials through aggregating ARCA
patients in an accessible, standardized, multicenter fashion
around the world;
• characterizing the phenotypic spectra for ARCAs, which will
inform treatment trial design and especially outcome selection
for future treatment trials;
• collecting real-world natural history data for ARCAs acquired
during daily clinical life across a large range of centers across
the world, thereby informing design, planning, and modeling
of treatment trials; and
• providing a continuous database backbone for trial-readiness
ataxia consortia around the world, e.g., the German DZNE
ARCA-EOA network (4), the PREPARE consortium (5),
PROSPAX (6), and ARCA GLOBAL (7).
In this overview, we will describe the main methodological
features and assets of the ARCA Registry, with examples on how
it is already being utilized to improve trial readiness in the field of
ARCAs, including its current use by multiple research networks.
It will also illustrate the registry’s potential for expansion to other
partners worldwide to promote trial readiness for ARCAs.
A GOOD CLINICAL PRACTICE- AND
GENERAL DATA PROTECTION
REGULATION-COMPLIANT GLOBAL
WEB-BASED REGISTRY: DATA CAPTURE,
DATA ACCESS, AND DATA SHARING
The ARCA Registry is built on WebSpirit (2mt Software, Ulm,
Germany), a web-based electronic data-capture system currently
Abbreviations: ADLs, activities of daily living; AGI, Ataxia Global Initiative;
ARCA, autosomal recessive cerebellar ataxia; DZNE, German Center for
Neurodegenerative Diseases; ESMI, European Spinocerebellar Ataxia Type
3/Machado-Joseph Disease Initiative; eCRF, electronic case report form; EMA,
European Medicines Agency; EOA, early-onset ataxia; ERDRI, European Rare
Disease Registry Infrastructure; ERN-RND, European Reference Network for
Rare Neurological Diseases; FARS, Friedreich Ataxia Rating Scale; GCP, good
clinical practice; GDPR, general data protection regulation; HSP, hereditary spastic
paraplegia; INAS, Inventory of Non-Ataxia Signs; MRI, magnetic resonance
imaging; NGS, next-generation sequencing; PGI-C, Patient’s Global Impression of
Change; PHQ-9, patient health questionnaire on depression and anxiety; PROM,
patient-reported outcome measure; SARA, Scale for the Assessment and Rating of
Ataxia; SPORTAX, Consortium “Sporadic Degenerative Ataxia with Adult Onset”;
PREPARE, Consortium “Preparing for therapies in autosomal recessive ataxias”;
PROSPAX, Consortium “An integrated multimodal PROgression chart in SPastic
atAXias”; SCA, spinocerebellar ataxia.
used in a variety of national and international medical research
consortia (Figure 1). The web-based implementation allows
direct access by registered clinicians and study teams from any
computer worldwide, as required for easy access in a global
multicenter setting. The fact that it uses the same technical
registry platform (WebSpirit) as one of the largest autosomal
dominant ataxia registries, namely, the spinocerebellar ataxia
(SCA)/ESMI registry (8, 9) and SCA Global (10), as well as
the large sporadic ataxia registry (SPORTAX) (11, 12) and
the Hereditary Spastic Paraplegia (HSP) Registry, allows for
cross talk and joint analysis not only across the manifold
ARCAs captured in the ARCA Registry itself but also with
SCAs, sporadic ataxias, and even HSPs. This is further
facilitated by aligning all key electronic case report forms
(eCRFs) between these major ataxia registries. The registry
platform is GCP-compliant: an audit trail is maintained to
track changes to recorded data, a detailed rights and role
management system limits access to entered data for each
individual system user, and quality assurance is supported
by an integrated online-monitoring system. Moreover, it is
fully compliant with the European Union GDPR based on
the following features: use of unique pseudonyms generated
with a secure one-way hash function to restrict the use of
personally identifiable data to local sites; separation of processing
activities through assignment of user roles (e.g., data entry,
monitoring, and data management) and restriction of access
to data; record and transfer only of pseudonymized data; all
access to data through encrypted connections; and servers
located within the EU. Participating sites maintain access to
their data entered in the ARCA Registry, with the possibility
to easily export and systematically analyze locally aggregated
datasets. Access to full multisite datasets is provided for specific
projects upon request by a standardized project template
and provided to the project submitter after evaluation of
the request.
The physician-reported multidomain datasets in the ARCA
Registry are the core of a larger systematic multi-component
ARCA database cluster (Figure 1). For longitudinal collection
of biomaterials, the ARCA Registry is linked to an ARCA
biomaterial database built on REDCap. To facilitate whole-
exome and whole-genome sequencing in all patients with
unsolved ARCA, the ARCA Registry is moreover linked
to next-generation sequencing (NGS) data on the genomics
research platform GENESIS (13, 14). GENESIS is a user-
friendly collaborative cloud-based analysis and matchmaking
platform that encompasses the largest ataxia NGS dataset
collection worldwide (>2,000 ataxia NGS datasets), aggregated
via the PREPARE consortium (PREPARE-GENESIS) (see below).
While the ARCA Registry and the GENESIS platform are
two distinct databases, subjects from the registry are linked
to the GENESIS platform via an ID generated by the ARCA
biomaterial database. Ongoing developments of this multi-
component ARCA database cluster will include an ARCA multi-
study database as a repository for features of digital outcomes
such as magnetic resonance imaging (MRI), digital-motor
sensors (APDM, Q-Motor), and optical coherence tomography
and for patient-driven entry of patient-reported outcome
measures (PROMs).
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FIGURE 1 | Platform and database infrastructure of the ARCA Registry. Graphical user interface of the web-based ARCA Registry, with display of a representative
electronic case report form (eCRF) and embedding in the larger database infrastructure. The front-end of the software and the main core of eCRFs are shared with
other major ataxia and rare disease registries (e.g., the HSP registry used by the TreatHSP network), making the ARCA Registry user friendly and convenient for joint
analysis of data across genetic ataxias, sporadic ataxias, and hereditary spastic paraplegia (HSP) registries.
CAPTURING PHENOTYPIC SPECTRA,
PHENOTYPIC EVOLUTION, AND DISEASE
PROGRESSION OF AUTOSOMAL
RECESSIVE CEREBELLAR ATAXIAS: THE
ELECTRONIC CASE REPORT FORMS
The eCRFs of the ARCA Registry are designed to characterize
the clinical heterogeneity of phenotypic spectra and natural
history phenotypic evolution of ARCAs, thus helping in the
selection of outcomes and planning of upcoming treatment
trials (sample size calculation, trial duration, etc.) as well-
modeling of trial endpoints and treatment effects. Different
degrees of eCRFs details—characterized as “core,” extended,”
and “optional” datasets—allow data capture tailored to the
participating site’s variable interests and resources (Table 1). In
brief, the eCRFs include clinical scales and composite measures,
clinician-reported outcome measure and PROMs, biomarker
outcomes, and quantitative performance measures:
• The core dataset in theARCA Registry comprises demographic
data (with ethnic background), genetic diagnosis (with types
of sequencing performed), different scores to measure disease
severity like the Friedreich Ataxia Rating Scale (FARS)
Functional Stage (15), the Scale for the Assessment and Rating
of Ataxia (SARA) (16), systematic phenotyping using the
Inventory of Non-Ataxia Signs (INAS) (17) with customized
amendments (e.g., bradykinesia, ptosis, or the head impulse
test), the presence and onset of typical clinical ARCA features
(e.g., ataxia, epilepsy, cognitive impairment, and diabetes),
ARCA biomarkers (serum and neurophysiology), and relevant
comorbidities (including alcohol intake).
• The extended dataset adds questionnaires on health status
and depression (EQ-5D and PHQ-9) (18, 19), disease-
relevant medication and treatment effects, and a summary of
MRI findings.
• Optional datasets include the possibility to report pediatric
features (e.g., pregnancy and birth or developmental
milestones), and the ARSACS Disease Severity Index as a
disease-specific outcome measure (20).
The Patient’s Global Impression of Change (PGI-C; core dataset)
(21, 22) and the FARS Activity of Daily Living (ADL; extended
datasets) (15) have recently been implemented as “anchor
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TABLE 1 | Case report forms in the ARCA Registry.
Case report form Items/description Dataset
Demographics Sex, year of birth, dexterity, ethnic background, consanguinity, siblings Core
Diagnosis Genetic diagnosis, type of sequencing so far, mutation/repeats (optional) Core
Biomarkers Biosampling for research, biochemical markers (e.g., AFP and Vit E),
neurophysiology (e.g., NCS and MEP)
Core
Clinical features Onset, course (progressive, episodic), multisystemic involvement (e.g., eyes,
epilepsy, diabetes, heart, and kidney), cognition, behavior, and mainstream
school
Core
Comorbidity Alcohol, CNS/PNS unrelated to ARCA, psychiatric, and review of systems;
with possible contribution to impairment
Core
SARA Scale for the Assessment and Rating of Ataxia Core
INAS Inventory of Non-Ataxia Signs Core
FARS Stage functional staging, mobility milestones (e.g., cane, walker, and wheelchair) Core (since 2020)
PGI-C Patient’s Global Impression of Change since last visit Core (since 2021)
EQ-5D/EQ-5D-Y Self-rated assessment of health status Extended
PHQ-9 Patient health questionnaire on depression and anxiety Extended
MRI Summary of imaging features (e.g., atrophy and signal abnormalities) Extended
Medication Disease-specific; generic name, dose, target symptom, and outcome
(optional)
Extended
FARS ADL Activities of daily living Extended (since 2021)
Pediatric features Pregnancy, gestation, weight, head circumference, and
development/walking
Optional
ARSACS DSI Disease severity index for ARSACS Optional
AFP, alpha-fetoprotein; MEP, motor-evoked potential; NCS, nerve conduction studies; CNS, central nervous system; PNS, peripheral nervous system.
measures,” i.e., measures reflecting the patient’s subjective
experience of disease progression and functional impairment,
which serve as reference measures helping to evaluate the
significance of changes and effect sizes observed for the
longitudinal clinical and biomarker data in the registry.
CROSS-CONTINENTAL MULTICENTER
CAPTURE AROUND THE WORLD: THE
CONTRIBUTING CENTERS
The ARCA Registry captures ARCAs from centers around the
world (Figure 2). While initially mainly capturing centers from
countries across Europe, the scope of the ARCA Registry has
continuously grown in the last 5 years currently to now more
than 30 sites from 15 countries. The registry has an active
strategy to recruit centers from underrepresented countries to
strengthen its global representation of ARCAs, regarding both
disease prevalence and variable genetic/ethnic backgrounds.
Participation is possible upon request. Minimum requirements
are the commitment to contribute CRFs of at least the basic
phenotype (see above) and to aim for longitudinal follow-ups.
CURRENT DATA IN THE ARCA REGISTRY:
A DESCRIPTIVE OVERVIEW OF 800
PATIENTS AND 1,500 VISITS
From its foundation in 2013 until now, more than 800 patients
with almost 1,500 visits have been recruited to theARCARegistry.
In the past 5 years, there has been a considerable increase in
FIGURE 2 | Contributing centers. The ARCA Registry is a growing,
cross-continental multicenter registry, with more than 30 contributing sites in
15 countries by the end of 2020.
longitudinal data, currently reaching up to eight annual follow-
up visits in the first patients (Figure 3A). Follow-up core datasets
including SARA or INAS from at least two visits and 13 sites
are available in >300 patients. Follow-up extended datasets such
as MRI summary data or the self-rated assessment of health
status by EQ-5D from at least two visits are available from
>200 patients. In addition to its longitudinal coverage, theARCA
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FIGURE 3 | Recruitment and patient characteristics in the ARCA Registry. (A) Recruitment and coverage. Recruitment of patients is continuous since 2013, reaching
more than 800 patients with up to eight longitudinal assessments by the end of 2020. Longitudinal data with at least two assessments are available in about 200–300
patients. (B) Baseline characteristics of patients. Patients in the ARCA Registry span the full range of ages and disease stages. (C) Genetic diagnoses in the ARCA
Registry, with a list of the 10 most frequent genetic causes.
Registry also captures patients with a broad range of ages and
disease stages (Figure 3B). While—in keeping with the early
onset of ARCAs (1, 2) −60% of patients have symptom onset
before 40 years of age, 40% of patients have later onset, up
to 80 years of age. Ataxia severity at baseline visits have been
recorded as mild (SARA: ≤8), moderate (8–16), and severe
(>16) in 16, 41, and 43% of patients, respectively. Sixty-five
percent of patients have an established genetic diagnosis. The
most frequent diagnoses in the ARCA Registry are ARSACS
(∼120 patients, 14%), Friedreich ataxia (∼90 patients, 11%), and
SPG7 (∼40 patients, 4%; see Figure 3C for the 10 most frequent
ARCAs). Except for the enrichment of ARSACS—which is an
overrepresentation due to themajor contribution of participating
sites in Quebec—the ARCA Registry provides prevalence data
that are generally consistent with expectations from the literature
(1, 23). Patients in the ARCA Registry who do not have a genetic
diagnosis yet (currently 35%) are included in a coordinated NGS
effort on a continuous basis to make a diagnosis or to identify
novel genes, via the PREPARE-GENESIS platform (see above).
The ARCA Registry with its phenotypic and longitudinal data
has enabled large clinico-genetic cohort studies to delineate
the phenotypic spectrum and longitudinal disease progression
of major and novel ARCAs. It thus fulfills the requirements
of primary datasets that can be used to describe natural
history progression models and plan treatment trials in almost
all of the most frequent ARCAs, including pharmacometric
modeling of outcome measures and treatment effects. For
example, for RFC1-ataxia, it has helped to reveal multisystemic
phenotypes mimicking cerebellar type multiple system atrophy
and progressive supranuclear palsy, and hyperkinetic movement
disorders such as chorea and dystonia, and provided first sample
size calculations based on longitudinal SARA assessments (24).
For COQ8A/ADCK3-ataxia, the ARCA Registry facilitated the
delineation of clinico-genetic associations, and the longitudinal
analysis of SARA scores has provided the first systematic, group-
based evidence for a possible treatment effect of coenzyme Q10
(25). Similarly, the ARCA Registry has enabled the natural history
of POLG-related ataxia to be documented through longitudinal
SARA and INAS assessments (26). The systematic assessment
of patients with as-yet-unknown genetic molecular diagnoses
means that—when the underlying gene is discovered—there are
already established longitudinal progression data, as exemplified
for patients found to carry pathogenic variants in the novel
ARCA gene PRDX3 (27).
MEETING CRITERIA OF THE EUROPEAN
RARE DISEASE REGISTRY




European authorities including the European Medicines Agency
(EMA) have highlighted the potential of disease registries to
provide real-world evidence that can complement preclinical,
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clinical, and even post-marketing data especially for rare diseases
(3). At the same time, however, they have also put forward
clear standards for data collection and quality criteria for disease
registries that aim to meet this goal.
European Medicines Agency Registry
Standards for Data Collection
The ARCA Registry captures the key EMA data elements (3),
including administrative information (e.g., site, contact dates,
registry entry and exit dates, and reason for registry exit), patient
data (e.g., age, sex, and alcohol as lifestyle factor), disease features
(including diagnosis, disease duration, severity/staging, genetic
information, and biochemical tests if appropriate), relevant
comorbidities, and disease-related or relevant concomitant
medical treatment (Table 2). The ARCA Registry is also enrolled
in the European Directory of Registries of the European Rare
Disease Registry Infrastructure (ERDRI.dor). As a constituent
registry of the evolving Rare Neurological Disease Registry of
the European Research Network on Rare Neurological Diseases
(ERN-RND) (28), the ARCA Registry will provide the common
data elements defined by the ERDRI (29), which adds more
systematic coding of diagnosis (Orpha code), genetic diagnosis
(HGVS) or phenotype (HPO), resources for research (e.g.,
biosampling and link to biobank), and a classification of disability
(Table 3). As a cross-disease database, the ERN-RND registry
collects general information on demographics, genetics, and
phenotype, which allows the identification of centers that look
after specific (and often genetically defined) patient groups. By
contrast, as a disease-group specific database, the ARCA Registry
collects complementary in-depth data to enable trial readiness in
recessive ataxias. Both registries are well-interconnected, as the
common ERN dataset can be easily extracted from the ARCA
Registry and imported into the ERN-RND registry. This link with
the ERN-RND registry also adopts the FAIR principles in the
ARCA Registry, ensuring that its data are f indable, accessible,
interoperable, and reusable between countries (30).
European Medicines Agency Standards for
Data Quality
In line with the EMA standards of data quality (3), the
ARCA Registry aims for consistency, completeness, accuracy,
and timeliness. Consistency of data is facilitated by common
standardized eCRFs, by clearly defined variables and selection of
questions with binary outcomes, and by the implementation of
clinical scales with high interrater reliability, especially SARA,
INAS, and FARS stage or ADL (15, 16, 31). Completeness of
data in core datasets is automatically checked online as the first
step of a continuous database-embeddedmonitoring process; this
resulted in 95% (e.g., for clinical features of ARCAs) to 99% (e.g.,
for SARA or INAS) CRF completion rate. Following automated
online control of data plausibility and consistency within and
between different CRFs at the time of data entry, accuracy of data
is afterwards controlled offline in the second monitoring step.
Recruitment numbers including availability and completeness
are regularly disseminated in systematic, standardized reports of
networks that use the ARCA Registry.
TABLE 2 | Implementation of EMA guidelines on patient registries.
Data element Data items ARCA registry
Administrative information Name of center X
Availability of informed consent X
Registry entry date X
Registry exit date and
circumstances
X
Dates of encounters X
Patient data Age or birthdate X
Gender X
Lifestyle factors (alcohol, smoking,
employment)
X
Disease characteristics Diagnosis X
















Start date (X) *




Pregnancy Pregnancy status/outcome ×
PROMs Patient-reported outcomes in
clinical practice
• **
Safety reporting adverse events/reactions • ***
EMA, European Medicines Agency.
*Indirect assessment by longitudinal capture of current treatment; **planned; ***once
closer to monitoring of drug treatments.
NETWORKS USING THE ARCA REGISTRY
AS THEIR INFRASTRUCTURE BACKBONE
The ARCA Registry is being used not only by more than 30
single sites but also by several leading ARCA networks in Europe
and worldwide.
German Autosomal Recessive Cerebellar
Ataxias/Early-Onset Ataxia Network
The German network on ARCAs and EOAs, launched in 2013
by the German Center for Neurodegenerative Diseases (DZNE),
comprises five major German ataxia sites (Tübingen, Bonn,
Munich, Magdeburg, and Rostock). The network has established
the first version of the ARCA Registry, which was co-hosted by
the Ataxia Study Group. Every effort was made to ensure that
the Registry is fully aligned in its data fields and database system
with other major SCA and sporadic ataxia registries (32), likewise
hosted by the Ataxia Study Group. Since then, the German
ARCA/EOAnetwork has contributed>400 subjects to the ARCA
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Pseudonym Patient’s pseudonym X
Personal information Date of birth (X)*
Sex at birth X
Patient status Alive or dead X
Date of death X
Care pathway First contact with specialized center X
Disease history Age at onset of first symptoms/signs X
Age at diagnosis or first consultation X
Diagnosis Diagnosis of rare disease in Orpha code X
Genetic diagnosis in HGVS X
Undiagnosed case in HPO terms X
Research Agreement to be contacted for research X
Consent to reuse data for other research X
Biological sample available X
Link to biobank where biosample is stored X
Disability Classification of functioning/disability X
*Restricted to year of birth.
Registry and provides monthly reports on its recruitments to the
ARCA Registry.
PREPARE
PREPARE (Preparing for therapies in autosomal recessive
ataxias) was launched in 2016 as an EU-funded (E-RARE JTC
2015) rare disease network; it was one of the first dedicated
ARCA trial-readiness networks. Utilizing the complementary
expertise from many ARCA centers and international ARCA
networks, it was established to facilitate all crucial translational
steps from genetic profiling (including discovery of new genes)
to standardized preclinical trials, developing FDA-compliant
outcome measures, and registry-inventoried transnational trial-
ready cohorts, hereby fully building on the ARCA Registry as
its backbone. The network began with seven centers from across
Europe and Canada and has now expanded to >13 centers
including centers in Turkey, Iran, and New Zealand. Using the
extended site network and longitudinal dataset provided by the
ARCARegistry, PREPARE has run phenotype and natural history
studies on several ARCAs, e.g., RFC1 (24), COQ8A/ADCK3 (25),
RFC1, POLG (26), and PRDX3 (27).
PROSPAX
The network PROSPAX (An integratedmultimodal PROgression
chart in SPastic atAXias), launched in 2020 and funded by
the European Joint Program on Rare Diseases (EJP RD), will
establish a paradigmatic integrated trial-ready model of disease
progression and mechanistic evolution in spastic ataxias. It
hereby builds on a rigorous trial-like multicenter natural history
center study on the two flagship recessive ataxias ARSACS and
SPG7, combining longitudinal clinician- and patient-reported
digital andmolecular outcomes for these spastic ARCAs. It unites
all major European ARCA and HSP networks and includes
Canadian ARCA centers (>7 centers) to run this transatlantic
natural history study. PROSPAX hereby utilizes a “spin-off”
study registry version, which directly builds on the ARCA
Registry, with fully compatible pseudonymization procedure and
eCRFs, and where datasets will be integrated into the ARCA
Registry (and equally the HSP registry) at the end of the
study. PROSPAX also draws on all the other components of
the multi-component ARCA database cluster described above
(ARCA biomaterial database, GENESIS, and ARCA multi-study
database). By sharing the same core eCRFs and front-end with
the HSP Registry used by the TreatHSP network (33), this spin-
off version of the ARCA Registry enables direct cross talk with
the HSP registry and joint analysis with HSPs, which is of
high importance given the large genetic, molecular, and clinical
overlap between ataxias and HSPs (34).
ARCA Global
ARCA GLOBAL and its sister platform SCA GLOBAL together
comprise the Ataxia Global Initiative (AGI). The AGI presents
a worldwide multi-stakeholder (academia, industry, and patient
organizations) platform coordinating and preparing all necessary
steps for trial readiness in autosomal-dominant (SCA GLOBAL)
and autosomal recessive (ARCA GLOBAL) ataxias (7, 10). With
establishing trial-ready cohorts and cross-center harmonized
clinician-reported outcome measures and PROMs as one of its
key tasks, the AGI uses the ARCA Registry as one of its key
registries. This reflects the fact that the ARCA Registry already
captures all outcome measures that were stipulated by the AGI as
the common core set of clinical outcome measures to be used by
ataxia centers worldwide.Moreover, the AGI builds on the ARCA
Registry as one of its major trial-readiness resources, as this
registry readily allows data-download and dataset preparation
for further workup, e.g., by the Critical Path to Therapeutics for
the Ataxias (CPTA) consortium of the Critical Path Institute (C-
Path), which aims to prepare regulatory approval by the FDA and
the EMA for clinical endpoints in genetic ataxias.
In addition, the SPATAX network, which includes all types
(i.e., not only autosomal recessive) of ataxias and HSPs, has
contributed subsets of data to the ARCA Registry.
LIMITATIONS AND OUTLOOK
The ARCA Registry faces several limitations and open challenges
that remain be to be addressed:
• The sustainability of the ARCA Registry depends on strong
commitment by the contributing centers as well as project-
based funding, with fluctuations in patient recruitment,
participating sites, and monitoring performance. Technical
improvements and new software implementations often come
along with variable latencies. Even the “core dataset” may
exceed the possibilities of a clinical appointment in many
ataxia centers, but further minimization of the core dataset
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would need to be carefully weighed against the minimal
required data necessary to really help in preparing trial
readiness as well as against registry standards put forward by
public authorities. The timeliness of monitoring is governed
by batch monitoring of each site by site, which provides the
opportunity for focused local revision of data and files but
also leads to periodic delays for those sites that had just
been monitored.
• Patients with the same genetically defined ARCA are
still dispersed in different ataxia registries, e.g., because
of identification of novel autosomal recessive genes in
sporadic late-onset ataxia patients (e.g., RFC1) who have
so far been collected in a sporadic ataxia registry (e.g., the
SPORTAX registry).
• The ARCA Registry does not cover all aspects of each
ARCA disease, or may cover it with measures that are too
broad for clinical trial design in a specific ARCA disease.
While the global phenotype or the progression of ataxia as
measured by the SARA score is assessed, more fine-grained
motor (e.g., walking speed) and especially a larger array
of non-motor features (e.g., the cerebellar cognitive-affective
syndrome) are not captured. Moreover, selected eCRFs and
non-ataxia scales like the INAS were primarily implemented
to systematically capture disease phenotypes but might show
less responsiveness to change. Thus, for capturing the natural
history of certain ARCAs, the ARCA Registry might need to
be complemented by additional eCRFs. Registry spin-offs such
as PROSPAX registry, however, exemplify that the registry
infrastructure can indeed be readily adapted to meet the needs
of such natural history studies.
• Finally, recruitment into the ARCA Registry is still biased
toward patients from Europe or of European descent, which
leads to an underrepresentation of ARCAs with other
ethnic/genetic as well as sociocultural backgrounds. Structural
disadvantages (especially availability of local person and
funding resources for data-entry) and language barriers may
hamper a more global dissemination of the ARCA Registry.
The eCRFs, the registry software, and templates for an
application to a local institutional review board are all available
in English language, but additional translations and country-
specific adaptations may help to increase the scope.
CONCLUSIONS
The ARCA Registry has (i) enabled the harmonization of
clinical outcomes across ataxia centers around the world; (ii)
has demonstrated its capacity to act as a centralized database
for genotype–phenotype and natural history studies in the
>100 ARCAs, already exemplified for COQ8A-, RFC1-, and
POLG-related ataxias; and (iii) aggregates the necessary large-
scale longitudinal progression datasets for calculating sample
sizes, modeling trial designs and randomization procedures,
and running pharmacometric models simulating treatment effect
sizes for anticipated clinical trials. Given its adoption by many
international ARCA sites and networks; its GCP, GDPR, and
EMA compliance; its web-based data capture; and its connections
to a constantly growing multi-component ARCA database
cluster, the ARCA Registry is well-placed to become a global
trial-readiness registry for ARCAs.
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